Similarly, SMARCA4 mutations in patients with NSCLC were associated with improved survival after ICI therapy, suggesting that SMARCA4 detection may help assess the sensitivity of patients to immunotherapy [99]. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.